Plasma sphingolipids and depressive symptoms in coronary artery disease

Adam Dinoff, Mahwesh Saleem, Nathan Herrmann, Michelle M. Mielke, Paul I. Oh, Swarajya Lakshmi Vattem Venkata, Norman Haughey, Krista L. Lanctôt

Research output: Contribution to journalArticle

Abstract

Background: Depression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects. Methods: Depressive symptoms were measured using the depression subscale of the self-reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high-performance liquid chromatography-coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log-transformed concentrations of plasma sphingolipids and depressive symptoms. Results: A total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7% male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p =.026) and C18:0 (β = 0.209, p =.023) and sphingomyelin SM18:1 (β = 0.210, p =.024) were significantly associated with higher HADS depression subscale score after adjusting for covariates. Conclusion: Sphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.

Original languageEnglish (US)
Article numbere00836
JournalBrain and Behavior
Volume7
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Sphingolipids
Coronary Artery Disease
Depression
Linear Models
Sphingomyelins
Anxiety
Electrospray Ionization Mass Spectrometry
Tandem Mass Spectrometry
Fasting
High Pressure Liquid Chromatography
Regression Analysis

Keywords

  • coronary artery disease
  • depressive symptoms
  • sphingolipid

ASJC Scopus subject areas

  • Behavioral Neuroscience

Cite this

Dinoff, A., Saleem, M., Herrmann, N., Mielke, M. M., Oh, P. I., Venkata, S. L. V., ... Lanctôt, K. L. (2017). Plasma sphingolipids and depressive symptoms in coronary artery disease. Brain and Behavior, 7(11), [e00836]. https://doi.org/10.1002/brb3.836

Plasma sphingolipids and depressive symptoms in coronary artery disease. / Dinoff, Adam; Saleem, Mahwesh; Herrmann, Nathan; Mielke, Michelle M.; Oh, Paul I.; Venkata, Swarajya Lakshmi Vattem; Haughey, Norman; Lanctôt, Krista L.

In: Brain and Behavior, Vol. 7, No. 11, e00836, 01.11.2017.

Research output: Contribution to journalArticle

Dinoff, A, Saleem, M, Herrmann, N, Mielke, MM, Oh, PI, Venkata, SLV, Haughey, N & Lanctôt, KL 2017, 'Plasma sphingolipids and depressive symptoms in coronary artery disease', Brain and Behavior, vol. 7, no. 11, e00836. https://doi.org/10.1002/brb3.836
Dinoff A, Saleem M, Herrmann N, Mielke MM, Oh PI, Venkata SLV et al. Plasma sphingolipids and depressive symptoms in coronary artery disease. Brain and Behavior. 2017 Nov 1;7(11). e00836. https://doi.org/10.1002/brb3.836
Dinoff, Adam ; Saleem, Mahwesh ; Herrmann, Nathan ; Mielke, Michelle M. ; Oh, Paul I. ; Venkata, Swarajya Lakshmi Vattem ; Haughey, Norman ; Lanctôt, Krista L. / Plasma sphingolipids and depressive symptoms in coronary artery disease. In: Brain and Behavior. 2017 ; Vol. 7, No. 11.
@article{fd169aff54734509a8d5cb419b38f187,
title = "Plasma sphingolipids and depressive symptoms in coronary artery disease",
abstract = "Background: Depression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects. Methods: Depressive symptoms were measured using the depression subscale of the self-reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high-performance liquid chromatography-coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log-transformed concentrations of plasma sphingolipids and depressive symptoms. Results: A total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7{\%} male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p =.026) and C18:0 (β = 0.209, p =.023) and sphingomyelin SM18:1 (β = 0.210, p =.024) were significantly associated with higher HADS depression subscale score after adjusting for covariates. Conclusion: Sphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.",
keywords = "coronary artery disease, depressive symptoms, sphingolipid",
author = "Adam Dinoff and Mahwesh Saleem and Nathan Herrmann and Mielke, {Michelle M.} and Oh, {Paul I.} and Venkata, {Swarajya Lakshmi Vattem} and Norman Haughey and Lanct{\^o}t, {Krista L.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/brb3.836",
language = "English (US)",
volume = "7",
journal = "Brain and Behavior",
issn = "2157-9032",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Plasma sphingolipids and depressive symptoms in coronary artery disease

AU - Dinoff, Adam

AU - Saleem, Mahwesh

AU - Herrmann, Nathan

AU - Mielke, Michelle M.

AU - Oh, Paul I.

AU - Venkata, Swarajya Lakshmi Vattem

AU - Haughey, Norman

AU - Lanctôt, Krista L.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: Depression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects. Methods: Depressive symptoms were measured using the depression subscale of the self-reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high-performance liquid chromatography-coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log-transformed concentrations of plasma sphingolipids and depressive symptoms. Results: A total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7% male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p =.026) and C18:0 (β = 0.209, p =.023) and sphingomyelin SM18:1 (β = 0.210, p =.024) were significantly associated with higher HADS depression subscale score after adjusting for covariates. Conclusion: Sphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.

AB - Background: Depression is highly prevalent in individuals with coronary artery disease (CAD) and increases the risk of future cardiac events and mortality. Sphingolipids have been implicated in the pathophysiology of both CAD and depression. This study assessed the association between plasma sphingolipid concentrations and depressive symptoms in CAD subjects. Methods: Depressive symptoms were measured using the depression subscale of the self-reported Hospital Anxiety and Depression Scale (HADS). Sphingolipid concentrations were measured from fasting plasma samples using high-performance liquid chromatography-coupled electrospray ionization tandem mass spectrometry (LC/MS/MS). Linear regression models were used to assess associations between log-transformed concentrations of plasma sphingolipids and depressive symptoms. Results: A total of 111 CAD patients (mean (SD) age = 63.6 ± 6.4, 84.7% male) were included. In linear regression analyses, higher plasma concentrations of ceramides C16:0 (β = 0.204, p =.026) and C18:0 (β = 0.209, p =.023) and sphingomyelin SM18:1 (β = 0.210, p =.024) were significantly associated with higher HADS depression subscale score after adjusting for covariates. Conclusion: Sphingolipids, in particular the ceramide species C16:0 and C18:0 and the sphingomyelin species SM18:1, may be implicated in the pathophysiology of depression in CAD. The association between plasma sphingolipid concentrations and depression should be further examined in CAD patients and in other populations.

KW - coronary artery disease

KW - depressive symptoms

KW - sphingolipid

UR - http://www.scopus.com/inward/record.url?scp=85034820060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034820060&partnerID=8YFLogxK

U2 - 10.1002/brb3.836

DO - 10.1002/brb3.836

M3 - Article

C2 - 29201542

AN - SCOPUS:85034820060

VL - 7

JO - Brain and Behavior

JF - Brain and Behavior

SN - 2157-9032

IS - 11

M1 - e00836

ER -